Global Health Estimate of Invasive Mycobacterium chimaera Infections Associated with Heater-Cooler Devices in Cardiac Surgery by Sommerstein, Rami et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Global Health Estimate of Invasive Mycobacterium chimaera Infections
Associated with Heater-Cooler Devices in Cardiac Surgery
Sommerstein, Rami; Hasse, Barbara; Marschall, Jonas; Sax, Hugo; Genoni, Michele; Schlegel, Matthias;
Widmer, Andreas F; Swiss Chimaera Taskforce
Abstract: Investigations of a worldwide epidemic of invasive Mycobacterium chimaera associated with
heater-cooler devices in cardiac surgery have been hampered by low clinical awareness and challenging
diagnoses. Using data from Switzerland, we estimated the burden of invasive M. chimaera to be 156-282
cases/year in 10 major cardiac valve replacement market countries.
DOI: https://doi.org/10.3201/eid2403.171554
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-151838
Published Version
Originally published at:
Sommerstein, Rami; Hasse, Barbara; Marschall, Jonas; Sax, Hugo; Genoni, Michele; Schlegel, Matthias;
Widmer, Andreas F; Swiss Chimaera Taskforce (2018). Global Health Estimate of Invasive Mycobac-
terium chimaera Infections Associated with Heater-Cooler Devices in Cardiac Surgery. Emerging Infec-
tious Diseases, 24(3):576-578.
DOI: https://doi.org/10.3201/eid2403.171554
Rami Sommerstein, Barbara Hasse,  
Jonas Marschall, Hugo Sax, Michele Genoni, 
Matthias Schlegel, Andreas F. Widmer, 
the Swiss Chimaera Taskforce1
Investigations of a worldwide epidemic of invasive Myco-
bacterium chimaera associated with heater–cooler devices 
in cardiac surgery have been hampered by low clinical 
awareness and challenging diagnoses. Using data from 
Switzerland, we estimated the burden of invasive M. chi-
maera to be 156–282 cases/year in 10 major cardiac valve 
replacement market countries.
Invasive Mycobacterium chimaera infection associated with heater–cooler devices (HCDs) in cardiac surgery 
was identified as a new disease entity in 2014 (1). The 
most likely pathogenesis involves aerosols transmitted 
from the HCD to the patient during surgery (2). As of Sep-
tember 2017, ≈120 cases have been recognized globally; 
mycobacterial device contamination at the manufacturing 
site of the LivaNova 3T (LivaNova, London, UK), the 
HCD market leader, seems to represent the most likely 
point source for the outbreak (3,4). The incubation period 
after exposure is long, with a median of 17 months (range 
3–72 months). Signs and symptoms are generally nonspe-
cific and include fatigue, fever, and weight loss. There is 
no established therapy, and the case-fatality rate is ≈50% 
(3,5). The disease appears to be rare and most commonly 
affects patients after valve replacement or other implant 
procedures in open heart surgery. Currently, the extent of 
the epidemic is unknown. We aimed to estimate the global 
epidemiology of disseminated M. chimaera disease as-
sociated with open heart surgery. The study followed the 
Guidelines for Accurate and Transparent Health Estimates 
Reporting (6).
The Study
Case Definition 
Switzerland was the leading country in recognizing and re-
searching the global outbreak of M. chimaera disease asso-
ciated with open heart surgery (1,2,5,7,8). This recognition 
included early establishment of a nationwide interdisciplin-
ary expert group consisting of hospital epidemiologists, in-
fectious disease physicians, cardiac surgeons, perfusionists, 
microbiologists, and consultants from the Swiss Agency 
for Therapeutic Products and the Federal Office of Public 
Health (collectively called the Swiss Chimaera Taskforce). 
This expert group has issued nationwide recommendations 
on case definition, lookback mechanisms, and infection 
prevention measures and releases updates on proven cases 
(9,10). We identified cases for our study through review 
of clinical and microbiological data, based on a previously 
published case series (7) and on reports to the Swiss Chi-
maera Taskforce. A proven case was defined as a case in a 
patient with previous open heart surgery, including implant 
surgery, and the subsequent detection of the M. chimaera 
outbreak strain from a sterile site.
Valve Replacements and HCDs in Use
Data on annual valve replacements performed during 
2008–2016 were available from the Swiss National Reg-
istry for Cardiac Surgery. We report aggregated data 
for mitral and aortic valves. Currently active HCDs 
with the reporting date of January 15, 2015, were sub-
mitted via an electronic spreadsheet to the Swiss Chi-
maera Taskforce.
Statistical Analyses
We obtained data on demographic development from the 
Swiss Federal Office of Statistics (11). By applying a linear 
regression model, we determined estimates of the annual 
prevalence per 1,000 valve replacement procedures for in-
dex surgeries from 2008 (the presumed beginning of the 
outbreak) through 2014 (taking the latency of disease man-
ifestation into account). Likewise, we calculated the yearly 
incidence of detected cases per 1,000,000 inhabitants from 
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2011 (the year of the first diagnosed case) through 2016. 
We determined best fit values and 95% CIs.
We identified 11 proven cases during January 2008–
September 2017 (Figure, panel A). The number of annual 
valve replacement procedures increased from 1,632 in 
2008 to 2,581 in 2016. During the same period, the popula-
tion of Switzerland increased from 7,593,494 to 8,327,126 
(Table). The annual estimated incidence of proven cases 
per 1 million inhabitants increased from 0.16 (95% CI 
0–0.37) in 2011 to 0.25 (95% CI 0.05–0.45) in 2016 (p = 
0.49). The prevalence per 1,000 valve replacement surger-
ies increased from 0.52 (95% CI 0–1.41) in 2008 to 0.94 
(95% CI 0.05–1.83) in 2014 (p = 0.49; Figure, panel B). 
The LivaNova 3T was the predominant HCD, in use by 
15 of 18 reporting cardiac surgery centers in Switzerland 
as of January 15, 2015, with 28 of 44 HCDs in use (64%). 
This rate is comparable with the worldwide LivaNova 3T 
market share of 70% (3).
The prevalence we found is similar to that in a previ-
ously published report of a relatively crude estimation (12) 
and about 4 to 7 times higher than a UK study based on 
national laboratory and hospital admissions data (13). The 
difference from the UK study can be explained by the ac-
tive case detection strategy in Switzerland, compared with 
the laboratory investigation in the United Kingdom (10,13).
Conclusions
The risk for M. chimaera in patients undergoing heart sur-
gery is similar to the risks for more widely known diseases 
such as parathyroid carcinoma (0.2/million/y), adrenal car-
cinoma (0.3/million/y), and congenital rubella syndrome 
(0.3/million/y) (14) that draw more attention but may have 
a smaller preventable proportion.
Considering an estimated 300,000 global annual valve 
replacement surgeries in the 10 major market countries and 
a US population of 323 million (12,15), we can extrapolate 
our findings to an annual incidence of 156–282 cases for 
the 10 major valve replacement markets and 51–80 cases 
in the United States alone. The currently known cases of 
invasive M. chimaera disease related to valve replacement 
reported from around the globe (n ≈120) are well below 
our estimate (3,4). Many countries in Europe did not report 
cases during the past few years, which is likely due to un-
derreporting or underdiagnosing (3,4).
The study has limitations. Invasive M. chimaera is not a 
mandatory reportable disease in Switzerland. However, the 
small size of the country and the close collaboration of the Swiss 
Chimaera Taskforce with the professional societies, as well as 
the broad coverage of the outbreak in television and newspa-
pers, decreases the likelihood of underreporting. In addition, 
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Figure. Incidence and prevalence of invasive M. chimaera cases 
in Switzerland since 2008. A) Yearly incidence per 1 million 
inhabitants according to the date of detection. B) Prevalence 
per 1,000 valve replacement surgeries according to the date of 
index surgery. Numbers of cases are projected on the left y-axis 
(bars); prevalence and incidence on the right y-axis (red circles). 
Gray bar indicates no. cases for January–August 2017. Linear 
regressions (red lines) were modeled for the respective window 
periods of interest; dotted lines indicate 95% CIs.
 
Table. Numbers of Mycobacterium chimaera cases, annual valve replacement procedures, and population in Switzerland, 2008–2017* 
Year 
Cases by date of 
index surgery 
Cases by date of 
detection No. aortic valves No. mitral valves Total no. valves Total population 
2008 1 0 1,291 341 1,632 7,593,494 
2009 2 0 1,238 691 1,929 7,701,856 
2010 1 0 1,306 398 1,704 7,785,806 
2011 0 2 1,468 274 1,742 7,870,134 
2012 2 1 2,032 273 2,305 7,954,662 
2013 1 1 2,017 164 2,181 8,039,060 
2014 4 2 2,120 441 2,561 8,139,631 
2015 0 1 2,039 472 2,511 8,237,666 
2016 0 3 2,112 469 2,581 8,327,126 
2017 0 1 NA NA NA NA 
*NA, not available. 
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the Swiss National Center for Mycobacteria in Zurich re-
ceives most, if not all, strains for confirmation. As demon-
strated previously, some patients may still be misinterpreted 
as having a rheumatologic disease (7), a potential reason for 
reporting bias. With valve replacement surgery as the denom-
inator, we may overestimate the incidence/prevalence of in-
vasive M. chimaera, as it is possible that some cases resulted 
from a procedure other than valve replacement surgery. All 
cases in Switzerland were associated with valve replacement 
surgery, however. Furthermore, many factors may influence 
incidence/prevalence on a global level, such as the predomi-
nant HCD brands in use, the degree of mycobacterial con-
tamination of these HCDs, the built hospital environment, 
positioning in the operating room, and the number and type of 
cardiac surgery procedures performed. Infection after HCD 
exposure is likely to be unevenly distributed and may be quite 
high in 1 hospital but near zero in a nearby hospital, even 
though each hospital uses the implicated HCD. It is essential 
to investigate this variability and understand the relative con-
tribution of some of these variables to the risk of infection. 
Nevertheless, it is likely that the aggregated risk derived from 
these factors is similar across national healthcare systems.
In summary, our data provide an estimate of the global 
burden of M. chimaera associated with open heart surgery, 
enabling policy makers to guide actions and to decrease the 
risk for transmission from HCDs. Our data suggest imple-
mentation of systematic lookback approaches in each country 
where LivaNova 3T HCDs have been used to optimize case 
finding. In addition, countries may consider mandatory re-
porting of invasive nontuberculous mycobacterial infections.
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